The role of TNFα in ulcerative colitis

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 930-941

  Sands, Bruce E ^a   Kaplan, Gilaad G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Inflammatory bowel disease; Infliximab; Therapy

Indexed keywords

ADALIMUMAB; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MERCAPTOPURINE; ONERCEPT; PENTOXIFYLLINE; PLACEBO; SEMAPIMOD; TETOMILAST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; MONOCLONAL ANTIBODY;

ABSCESS; ANTIGEN PRESENTING CELL; BASAL CELL CARCINOMA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COLON DISEASE; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE PREDISPOSITION; ENTERITIS; GENETIC ASSOCIATION; HISTOPLASMOSIS; HUMAN; LUPUS LIKE SYNDROME; LYMPHOCYTE DIFFERENTIATION; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPTIC NEURITIS; PATHOPHYSIOLOGY; PNEUMONIA; PROMOTER REGION; PROSTATE CANCER; RECTUM CARCINOMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TUBERCULOSIS; TUMOR NECROSIS FACTOR ALPHA PROMOTER GENE; ULCERATIVE COLITIS; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447650384     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007301623     Document Type: Review

References (99)

1. Hanauer SB, Present DH The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003 ; 3: 81-92.
2. Sands BE Biological therapies for ulcerative colitis. Acta Gastroenterol Belg. 2001 ; 64: 205-209.
3. Kornbluth A. Cyclosporine in inflammatory bowel disease. Curr Gastroenterol Rep. 1999 ; 1: 486-490.
4. Bach SP, Mortensen NJ Revolution and evolution: 30 years of ileoanal pouch surgery. Inflamm Bowel Dis. 2006 ; 12: 131-145.
5. Lovegrove RE, Constantinides VA, Heriot AG, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg. 2006 ; 244: 18-26.
6. Waljee A., Waljee J., Morris AM, Higgins PD Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006 ; 55: 1575-1580.
7. Hueting WE, Buskens E., van der Tweel I., Gooszen HG, van Laarhoven CJ Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg. 2005 ; 22: 69-79.
8. Podolsky DK Inflammatory bowel disease. N Engl J Med. 2002 ; 347: 417-429.
9. Lim WC, Hanauer SB Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004 ; 4: 66-85.
10. Neurath MF, Finotto S., Glimcher LH The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002 ; 8: 567-573.
11. Sandborn WJ, Targan SR Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 ; 122: 1592-1608.
12. Fuss IJ, Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004 ; 113: 1490-1497.
13. Sawa Y., Oshitani N., Adachi K., Higuchi K., Matsumoto T., Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med. 2003 ; 11: 175-179.
14. Pallone F, Blanco Gdel V, Vavassori P, Monteleone I, Fina D, Monteleone G. Genetic and pathogenetic insights into inflammatory bowel disease. Curr Gastroenterol Rep. 2003 ; 5: 487-492.
15. Podolsky DK The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2002 ; 16: 933-943.
16. Sandborn WJ, Hanauer SB Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 ; 5: 119-133.
17. Louis E. The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha. Acta Gastroenterol Belg. 2001 ; 64: 1-5.
18. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet. 2002 ; 11: 1281-1289.
19. Stucchi A., Reed K., O'Brien M., et al. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis. 2006 ; 12: 581-587.
20. Rossetti S., Actis GC, Fadda M., Rizzetto M., Palmo A. The use of the anti-tumour necrosis factor monoclonal antibody-infliximab- to treat ulcerative colitis: implications and trends beyond the available data. Dig Liver Dis. 2004 ; 36: 426-431.
21. Su C., Lichtenstein GR Recent developments in inflammatory bowel disease. Med Clin North Am. 2002 ; 86: 1497-1523.
22. Orholm M., Binder V., Sorensen TI, Rasmussen LP, Kyvik KO Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol. 2000 ; 35: 1075-1081.
23. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases ? Lancet. 2006 ; 367: 1271-1284.
24. Hampe J., Shaw SH, Saiz R., et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet. 1999 ; 65: 1647-1655.
25. Fisher SA, Hampe J., Macpherson AJ, et al. Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6. Eur J Hum Genet. 2002 ; 10: 259-265.
26. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 2000 ; 66: 1863-1870.
27. Sashio H., Tamura K., Ito R., et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics. 2002 ; 53: 1020-1027.
28. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997 ; 94: 3195-3199.
29. Wilson AG, de Vries N., Pociot F., di Giovine FS, van der Putte LB, Duff GW An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993 ; 177: 557-560.
30. Cao Q., Zhu Q., Wu ML, Hu WL, Gao M., Si JM Genetic susceptibility to ulcerative colitis in the Chinese Han ethnic population: association with TNF polymorphisms. Chin Med J (Engl). 2006 ; 119: 1198-1203.
31. Tremelling M., Waller S., Bredin F., Greenfield S., Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006 ; 12: 178-184.
32. Ahmad T., Armuzzi A., Neville M., et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003 ; 62: 527-535.
33. Facklis K., Plevy SE, Vasiliauskas EA, et al. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum. 1999 ; 42: 601-605 ; discussion 605-606.
34. Bouma G., Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999 ; 115: 294-300.
35. Bouma G., Xia B., Crusius JB, et al. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1996 ; 103: 391-396.
36. Mascheretti S., Croucher PJ, Schreiber S. Pharmacogenetics of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2004 ; 18: 597-609.
37. Funakoshi K., Sugimura K., Anezaki K., Bannai H., Ishizuka K., Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion. 1998 ; 59: 73-78.
38. Masuda H., Iwai S., Tanaka T., Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol. 1995 ; 46: 111-123.
39. MacDonald TT, Hutchings P., Choy MY, Murch S., Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990 ; 81: 301-305.
40. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994 ; 106: 1455-1466.
41. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993 ; 34: 1705-1709.
42. Braegger CP, Nicholls S., Murch SH, Stephens S., MacDonald TT Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 ; 339: 89-91.
43. Schmidt PT, Ljung T., Hartmann B., Hare KJ, Holst JJ, Hellstrom PM Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol. 2005 ; 17: 207-212.
44. Cao W., Fiocchi C., Pricolo VE Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol. 2005 ; 289: C1408 - C1416.
45. Sangfelt P., Carlson M., Thorn M., Xu S., Loof L., Raab Y. Local release of human neutrophil lipocalin (HNL), IL-8, and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis. Dig Dis Sci. 2002 ; 47: 2064-2069.
46. Murthy S., Flanigan A., Coppola D., Buelow R. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 ; 51: 522-531.
47. Ardizzone S., Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005 ; 65: 2253-2286.
48. Sandborn WJ, Hanauer SB, Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 ; 121: 1088-1094.
49. Lugering A., Schmidt M., Lugering N., Pauels HG, Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspasedependent pathway. Gastroenterology. 2001 ; 121: 1145-1157.
50. Van den Brande JM, Braat H., van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003 ; 124: 1774-1785.
51. Agnholt J., Kelsen J., Brandsborg B., Jakobsen NO, Dahlerup JF Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease: a possible target for infliximab treatment. Eur J Gastroenterol Hepatol. 2004 ; 16: 649-655.
52. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 ; 7: 83-88.
53. Probert CS, Hearing SD, Schreiber S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003 ; 52: 998-1002.
54. Ochsenkuhn T., Sackmann M., Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004 ; 16: 1167-1171.
55. Rutgeerts P., Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 ; 353: 2462-2476.
56. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004 ; 53: 1813-1816.
57. Jarnerot G., Hertervig E., Friis-liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study. Gastroenterology. 2005 ; 128: 1805-1811.
58. Regueiro M., Curtis J., Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006 ; 40: 476-481.
59. Mamula P., Markowitz J., Brown KA Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002 ; 34: 307-311.
60. Mamula P., Markowitz JE, Cohen LJ, von Allmen D., Baldassano RN Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004 ; 38: 298-301.
61. Oliva-Hemker M., Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis. 2002 ; 8: 112-128.
62. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 ; 359: 1541-1549.
63. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 ; 350: 876-885.
64. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 ; 4: 621-630.
65. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 ; 126: 19-31.
66. Siegel CA, Hur C., Korzenik JR, Gazelle GS, Sands BE Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006 ; 4: 1017-1024 ; quiz 976.
67. Legnani P., Kornbluth A. Newer therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2004 ; 7: 161-167.
68. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 ; 348: 601-608.
69. Watkins PE, Warren BF, Stephens S., Ward P., Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut. 1997 ; 40: 628-633.
70. Schreiber S., Rutgeerts P., Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005 ; 129: 807-818.
71. Sandborn WJ, Colombel JF, Panes J., Scholmerich J., McColm JA, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease. Am J Gasterenterol. 2006 ; 101: S434 (A1109).
72. Colombel JF, Sandborn WJ, Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 ; 132: 52-65.
73. Hanauer SB, Sandborn WJ, Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 ; 130: 323-333 ; quiz 591.
74. Sandborn WJ Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol. 2003 ; 17: 105-117.
75. Kenet G., Wardi J., Avni Y., et al. Amelioration of experimental colitis by thalidomide. Isr Med Assoc J. 2001 ; 3: 644-648.
76. Bauditz J., Wedel S., Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002 ; 50: 196-200.
77. Bariol C., Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002 ; 17: 135-139.
78. Fu CS, Conteas CN, LaRiviere MJ Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus. AIDS Patient Care STDS. 1998 ; 12: 903-906.
79. Reimund JM, Dumont S., Muller CD, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut. 1997 ; 40: 475-480.
80. Murthy S., Cooper HS, Yoshitake H., Meyer C., Meyer CJ, Murthy NS Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther. 1999 ; 13: 251-260.
81. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 1997 ; 40: 470-474.
82. Hanauer S., Miner PB Jr, Keshavarzian A. Randomized, double-blind, placebo-controlled, parallel arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis (UC) [abstract 814]. Abstract presented at: Digestive Disease Week ; May 19, 2002 ; San Francisco.
83. Lazarov M., Welihinda A., Muhr E. RDP58, a novel antiinflammatory peptide, inhibits multiple intracellular messenger pathways and transcription factors to block TNF-A, INF-g, and IL12 production [abstract 770]. Abstract presented at: Digestive Disease Week ; May 17, 2003 ; Orlando, Fla.
84. Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005 ; 21: 385-389.
85. Hommes D., van den Blink B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002 ; 122: 7-14.
86. Arseneau KO, Sultan S., Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006 ; 4: 1135-1142.
87. Kaser A., Mairinger T., Vogel W., Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001 ; 113: 930-933.
88. Lagares-Garcia JA, Kurek S., Collier B., et al. Colonoscopy in octogenarians and older patients. Surg Endosc. 2001 ; 15: 262-265.
89. Su C., Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002 ; 97: 2577-2584.
90. Kohn A., Prantera C., Pera A. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002 ; 34: 626-630.
91. Actis GC, Bruno M., Pinna-Pintor M., Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002 ; 34: 631-634.
92. Papadakis KA, Treyzon L., Abreu MT Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003 ; 18: 741-747.
93. Gornet JM, Couve S., Hassani Z., et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003 ; 18: 175-181.
94. Cooper JM, Patterson DJ, Thirlby RC Infliximab for ulcerative colitis: not a cure for severe disease [abstract M1949]. Abstract presented at: Digestive Disease Week ; May 17, 2003 ; Orlando, Fla.
95. Shapira SC, Panaccione R., Croitoru K. Infliximab therapy for steroid-refractory ulcerative colitis [abstract 183]. Abstract presented at: Canadian Digestive Disease Week ; February 22, 2003 ; Banff, Alberta, Canada.
96. Armuzzi A., De Pascalis B, Lupascu A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004 ; 8: 231-233.
97. Bermejo F., Lopez-Sanroman A., Hinojosa J., Castro L., Jurado C., Gomez-Beldal AB Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig. 2004 ; 96: 94-101.
98. Russell GH, Katz AJ Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004 ; 39: 166-170.
99. Eidelwein AP, Cuffari C., Abadom V., Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005 ; 11: 213-218.